Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
Third Rock Ventures is a venture capital firm established in 2007, with offices in Boston, Massachusetts, and San Francisco, California. The firm specializes in creating and building companies that translate scientific innovations into breakthrough medicines, particularly in the life sciences sector. Since its inception, Third Rock has raised a total of $3.8 billion and currently manages a portfolio of 72 companies.
The firm employs a team of 95 professionals, including 26 partners, who possess extensive backgrounds in pharmaceutical development, clinical science, and medical innovation. This diverse expertise enables Third Rock to lead a deep company formation model, actively participating in the development of its portfolio companies from inception through commercialization.
Third Rock Ventures primarily invests in Series A and B stages, with initial check sizes ranging from $30 million to $100 million. The firm focuses on transformational life science companies across various sectors, including biotech, diagnostics, medical devices, therapeutics, and digital health. Their investment strategy emphasizes addressing unmet medical needs, particularly in areas such as ultra-orphan and rare genetic disorders, cancer, cardiovascular disease, and neuropsychiatry.
The firm adopts a collaborative approach, working closely with scientific founders and expert advisors to develop strategies that prioritize patient needs. This hands-on operational support spans drug discovery, clinical strategy, business operations, and talent acquisition, ensuring that portfolio companies are well-equipped to succeed in the competitive healthcare landscape.
Third Rock Ventures has a diverse portfolio of 72 companies, which includes notable successes and innovative startups. The firm has achieved 19 IPOs and 23 acquisitions, demonstrating a strong track record in the life sciences sector. Among the notable portfolio companies are:
Additionally, the firm has 18 market-approved products, showcasing its commitment to bringing innovative solutions to market.
Abbie Celniker: Partner with a background in drug development and a focus on biotech.
Adam Tebbe: Partner specializing in operational strategy and company formation.
Alan Ezekowitz: Partner with expertise in clinical science and medical innovation.
Alison Connors: Partner with a strong background in pharmaceutical development.
Amanda Chan: Partner focusing on investment strategy and portfolio management.
Andrea van Elsas: Partner with experience in biotech and healthcare investments.
Angelo Severino: Partner specializing in early-stage investments in life sciences.
Ava Brunelle: Partner with a focus on digital health and therapeutics.
Cary Pfeffer: Partner with expertise in business operations and strategy.
Cath McGowen: Partner focusing on investment analysis and portfolio support.
Charles Homcy: Partner with a background in clinical research and drug development.
Chris Robinson: Partner specializing in operational support for portfolio companies.
Corey O’Keeffe: Partner with expertise in biotech and healthcare innovation.
Courtney Wallace: Partner focusing on investment strategy and market analysis.
Craig Muir: Partner with a strong background in life sciences investments.
Danielle Abdelahad: Partner specializing in early-stage biotech investments.
David Kaufman: Partner with expertise in clinical strategy and drug development.
David Moller: Partner focusing on operational support and company formation.
Divya Mathur: Partner with a background in healthcare investments.
Erin Moore: Partner specializing in digital health and therapeutics.
Gabriella Williams: Partner with expertise in investment strategy and portfolio management.
Greg O'Brien: Partner focusing on operational strategy and business development.
Hugo Hilton: Partner with a strong background in biotech investments.
Jason Gehrke: Partner specializing in early-stage investments in life sciences.
Jeb Keiper: Partner with expertise in clinical research and drug development.
Jeffrey Finer: Partner focusing on investment analysis and portfolio support.
Jeffrey Tong: Partner with a background in healthcare innovation.
Jefte Drijvers: Partner specializing in operational support for portfolio companies.
Jesper Gromada: Partner with expertise in biotech and healthcare investments.
Jigar Raythatha: Partner focusing on investment strategy and market analysis.
John Keilty: Partner with a strong background in life sciences investments.
Julia O'Connor: Partner specializing in early-stage biotech investments.
Julie Yang: Partner with expertise in clinical strategy and drug development.
Kelly Gaudet: Partner focusing on operational support and company formation.
Kevin Gillis: Partner with a background in healthcare investments.
Kevin Munnelly: Partner specializing in digital health and therapeutics.
Kevin Starr: Partner with expertise in investment strategy and portfolio management.
Laura Vitale: Partner focusing on operational strategy and business development.
Lee Venezia: Partner with a strong background in biotech investments.
Lisa Pepdjonovic: Partner specializing in early-stage investments in life sciences.
Lisa Purcell: Partner with expertise in clinical research and drug development.
Marc Crowley: Partner focusing on investment analysis and portfolio support.
Mark Levin: Partner with a background in healthcare innovation.
Mary Lynne Hedley: Partner specializing in operational support for portfolio companies.
Nasra Mohamed: Partner with expertise in biotech and healthcare investments.
Neil Exter: Partner focusing on investment strategy and market analysis.
Nicole Matthews: Partner with a strong background in life sciences investments.
Nicole Raby: Partner specializing in early-stage biotech investments.
Noreen Rizvi: Partner with expertise in clinical strategy and drug development.
Olie Luchitsky: Partner focusing on operational support and company formation.
Paul Melone: Partner with a background in healthcare investments.
Reid Huber: Partner specializing in digital health and therapeutics.
Richard Chesworth: Partner with expertise in investment strategy and portfolio management.
Richard Ransohoff: Partner focusing on operational strategy and business development.
Robert Tepper: Partner with a strong background in biotech investments.
Sara DeAmicis: Partner specializing in early-stage investments in life sciences.
Sascha Rosebush: Partner with expertise in clinical research and drug development.
Scott Frechette: Partner focusing on investment analysis and portfolio support.
Sophia Fox O'Connell: Partner with a background in healthcare innovation.
Stacey Hero: Partner specializing in operational support for portfolio companies.
Stephen Sherwin: Partner with expertise in biotech and healthcare investments.
Steve Paul: Partner focusing on investment strategy and market analysis.
Ton Schumacher: Partner with a strong background in life sciences investments.
Tracy Nicholson: Partner specializing in early-stage biotech investments.
Tracy Williams: Partner with expertise in clinical strategy and drug development.
Vyas Ramanan: Partner focusing on operational support and company formation.
Walter Kowtoniuk: Partner with a background in healthcare investments.
Yashu Liu: Partner specializing in digital health and therapeutics.
Yonglu Che: Partner with expertise in investment strategy and portfolio management.
Zoe Angell: Partner focusing on operational strategy and business development.
To pitch to Third Rock Ventures, founders should use the contact form available on their website at thirdrockventures.com. It is important to include a comprehensive pitch deck that outlines the business model, market opportunity, and team qualifications. Response times may vary, but founders are encouraged to follow up if they do not receive feedback within a reasonable timeframe.
On December 2, 2025, Third Rock Ventures made a significant investment of $165 million in Syremis Therapeutics, marking one of their four investments in the last 12 months. This investment underscores the firm's commitment to supporting innovative companies in the healthcare sector.
Throughout its history, Third Rock Ventures has achieved notable milestones, including 19 IPOs and 23 acquisitions, reflecting its strong track record in the life sciences industry. The firm continues to actively seek out and invest in transformative healthcare solutions.
Q?
What are Third Rock Ventures' investment criteria?
Third Rock Ventures invests in Series A and B stages, focusing on life science companies that address unmet medical needs, particularly in biotech, diagnostics, medical devices, therapeutics, and digital health.
Q?
How can founders pitch to Third Rock Ventures?
Founders can pitch through the firm’s website at thirdrockventures.com. It is advisable to include a clear description of the business model, market opportunity, and team background in the pitch deck.
Q?
What makes Third Rock Ventures different from other VC firms?
The firm emphasizes a hands-on operational support model, leveraging deep scientific expertise and a collaborative approach with founders to drive company formation and growth.
Q?
What is the geographic focus of Third Rock Ventures?
Third Rock Ventures primarily invests in companies based in the United States.
Q?
What is the typical check size for investments?
Third Rock Ventures typically writes checks ranging from $30 million to $100 million for their investments.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.